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1. Introduction 
Staphylococcus spp. are a challenge for the modern day medicine due to the complexity of 
disease process and presence and expression patterns of their respective virulence factors. 
The members of this genus possess many known toxins, multiple immunoavoidance 
mechanisms and adherence factors, most of which demonstrate transient, timed, and disease-
specific expression. They cause different types of infections in a host that are either planktonic, 
biofilm mediated or both. Sepsis and pneumonia are mainly caused by planktonic forms 
whereas, a whole range of diseases, namely, endophthalmitis, osteomyelitis, endocarditis, 
chronic skin infections, indwelling medical device infections, chronic rhino-sinusitis, and 
dental implantits are caused by the biofilmic form of the bacteria. Abscess can be caused by 
both of the forms (Harro et al., 2010). Staphylococci are human pathogen, known for their 
ability to become resistant to antibiotics. They have been associated, besides causing 
ophthalmic infections, with skin infections and sepsis. Methicillin resistant S. aureus 
(MRSA), in addition to resistance to other drugs, have emerged as a widespread cause of 
community infection as well. In this chapter, we describe the epidemiology and antibiotic 
resistance among S. aureus and other species with special reference to ophthalmic infections 
and focus on newer approaches for treatment of staphylococcus infection like phage therapy 
and vaccines. 
2. Staphylococcus in wound and eye infections 
Staphylococcus aureus, a gram-positive bacterium, discovered in 1880’s has been shown to be a 
potential pathogen causing infections such as minor skin infections and post-operative wound 
infection. Since the introduction of penicillin for the treatment, the mortality rate of individuals 
caused by S. aureus infection was about 80%. After emergence of penicillin resistance and 
introduction of methicillin in 1961, S. aureus developed resistance to methicillin due to 
acquisition of the mecA gene. During last 47 years, various hospital-associated methicillin-
resistant S. aureus (HA-MRSA) and later virulent community-associated MRSA (CA-MRSA) 
clones characterised by the presence of toxin Panton-Valentine-leukocidin (PVL), were 
reported (Deurenberg and Stobberingh, 2008).  
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Staphylococci have a special relationship with the eye. On one hand, almost all species of 
staphylococci may be present in the lid margins or conjunctiva as normal commensals 
without causing disease and on the other hand, they may cause severe eye infections which 
may result in irreversible blindness. Colonization by resident bacteria on the ocular surface 
can provide a defense by inhibiting the growth of virulent bacterial strains (Iskeleli et al., 
2005). However, in cases of trauma, or alteration of ocular tissue, indigenous flora may 
cause significant external and internal ocular infection (Speaker et al., 1991). In previous 
studies,  native ocular flora has been shown to be predominantly Staphylococcus species 
(Iskeleli et al., 2005). While normal ocular flora has been well established in the developed 
world, there have been very few publications from rest of the world. In a study of the normal 
conjunctiva from Rajasthan, India, 86% of eyes were culture positive for bacteria and 12% 
positive for fungi. The most common bacterial isolates were S. albus (32%) followed by 
S. aureus (28%) (Tomar et al., 1971). In another study from Masungbo, Sierra Leone where 
analysis of conjunctival swabs obtained from healthy eyes of 276 residents showed presence of 
coagulase-negative staphylococci (28.6%), fungus (26.0%) and S. aureus (19.9%) (Capriotti et al., 
2009). Many studies have not speciated the staphylococci from normal lids and conjunctiva, 
however, S. epidermidis is reported to be the most common species (McCulley et al., 1982). 
Both coagulase negative and positive staphylococci are responsible for a variety of anterior 
and posterior segment of eye infections such as blepharitis, canaliculitis, dacryocystitis, 
conjunctivitis, keratitis, scleritis, endophthalmitis, preseptal and orbital cellulitis etc. 
Important attributes of organisms causing ocular infections include virulence, invasiveness, 
numbers of organism entering the host tissues and the site of entry. Coagulase, lipase and 
esterase are important bacterial enzymes produced by staphylococci associated with 
blepharitis. Several characteristics of the host also determine the effect of bacterial virulence 
and development of disease. Age, use of drugs and contact lens use, trauma, surgery etc. 
may also influence the effect of virulence factors besides presence of risk factors e.g., dry eye 
states, chronic nasolacrimal duct obstruction, previous ocular disease etc. Tissue injury can 
result from direct action of bacteria and their toxins, as well as from bacteria induced 
inflammation. Immunopathologic activities include recruitment of polymorphonuclear cells, 
macrophages and lymphocytes. Mediators of inflammation such as histamine, tumour 
necrosis factor, cytokines, leukotrienes, prostaglandins etc. play important role in interaction 
with the bacteria and their removal or proliferation.  
 
Type of 
endophthalmitis 
Geographic 
area 
Duration 
of study 
No. of 
patients 
No, of 
isolates 
% of 
CoNS 
References 
Posttraumatic India 7 years 182 139 17.3 (Kunimoto 
et al., 1999b) 
Postoperative India 7 years 206 176 46.0 (Kunimoto 
et al., 1999a) 
Postoperative Singapore 5 years 34 21 57.0 (Wong and 
Chee, 2004) 
Postoperative India -- 80 37 62.6 (Srinivasan 
et al., 2002) 
Postoperative USA 5 years 278 313 49.9 (Benz et al., 
2004) 
Table 1. Prevalence of Staphylococcus species in endophthalmitis in various studies 
www.intechopen.com
 
Staphylococcal Infection, Antibiotic Resistance and Therapeutics 
 
249 
Inflammation of the lid margin or blepharitis may be anterior or posterior, the former 
involving the lash line and the latter meibomian glands. Both the conditions may be 
associated with skin diseases such as dermatitis (seborrhoeic or atopic) and rosacea. The 
anterior blepharitis with lash collarettes, crusting, lid ulceration and folliculitis is usually 
associated with S. aureus. The most common form of bacterial conjunctivitis is the acute 
mucopurulent form of S. aureus. This may be associated with obstruction of the Naso-
lacrimal duct. S. aureus conjunctivitis can become chronic due to its affinity for the eyelid 
margin and the resultant blepharitis. Coagulase negative staphylococci (CoNS), 
characteristically the endogenous flora of the ocular surface, are most of the common cause 
of postoperative endophthalmitis world over (Callegan et al., 2002; Kunimoto et al., 1999a, 
Benz et al., 2004, Wong and Chee, 2004). CoNS also rank first among bacteria causing 
posttraumatic endophthalmitis of which 45.3% isolates belong to gram positive cocci and 
17.3% of these were belong to gram positive bacilli (Kunimoto et al., 1999b).  Whereas CoNS 
do not commonly cause endogenous endophthalmitis, S. aureus have been reported from 
such infection (Callegan et al., 2002). Table 1. shows the prevalence of Staphylococcus species 
in patients with endophthalmitis. 
Microbial keratitis is a serious infection of the cornea that may be caused by a variety of 
organisms including staphylococci. Most of the studies from developed countries such as 
the USA (Liesegang and Forster, 1980, Ormerod et al., 1987, Asbell and Stenson, 1982) 
(except southern USA) and Australia (McClellan et al., 1989) have listed S. epidermidis or 
coagulase negative staphylococci as the leading cause of bacterial keratitis. In India, the 
leading cause of bacterial keratitis varies; however, some investigators have listed 
staphylococci as the commonest bacteria (Gopinathan et al., 2009). It is possible that some 
investigators may have considered S. epidermidis or coagulase negative staphylococci as a 
normal commensal of the conjunctiva and underreported the isolation of these organisms 
from corneal samples. Few studies have recommended application of certain criteria to 
determine significance of a positive culture from corneal scrapings (Gopinathan et al., 2009). 
Since S. epidermidis form the commonest commensal of the extraocular surfaces, it is highly 
probable that these organisms invade corneal tissues compromised by antimicrobial and / 
or corticosteroid therapy or trauma.   
For treatment of eye infections, antibiotics are usually administered topically as eye drops or 
intraocular injections, depending on the clinical condition. Other routes of administration 
such as subconjunctival injection are rarely used. Topically administered drugs have major 
advantage of localized drug effects, avoidance of hepatic first pass metabolism, and 
convenience. The disadvantage is low bioavailability to intraocular tissues, estimated to be 
only 1-10% (Davies, 2000). A large number of eye drops for topical therapy are available for 
extraocular eye infections, that include fluoroquinolones, macrolides, aminoglycosides, 
glycopeptides, tetracyclines, chloramphenicol, Neosporin (bacitracin, neomycin, polymyxin).  
A broad range of three generations of fluoroquinolones are available such as ciprofloxacin 
(0.3%), ofloxacin (0.3%), levofloxacin (0.5% and 1.5%) , gatifloxacin (0.3%) and moxifloxacin 
(0.5%, preservative free) as eye drops also. Gatifloxacin and moxifloxacin, the newer fourth 
generation fluoroquinolones that target both DNA gyrase and topoisomerase IV are highly 
effective against gram positive bacteria including staphylococci in human and animal 
corneal ulcer model (Romanowski et al., 2005, Aliprandis et al., 2005). However, gatifloxacin 
was shown to be more effective than moxifloxacin against staphylococci (Reddy et al., 2010). 
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Fluoroquinolone eye drops are widely used for prophylaxis before eye surgery to prevent 
postoperative infection, most commonly caused by CoNS. Recently, intracameral injection 
of moxifloxacin has been found to be safe and effective in reducing the rate of postoperative 
endophthalmitis following cataract surgery (Lane et al., 2008).    
Historically, the aminoglycosides have been the mainstay in the treatment of ocular 
infections. However, increasing resistance has limited their use in recent years in the 
treatment of staphylococcal infections. Glycopeptides such as vancomycin and teicoplanin 
the bactericidal antibiotics which inhibit peptidoglycan synthesis in the bacterial cell wall by 
complexing with cell wall precursors are highly effective against staphylococci including 
methicillin resistant staphylococci. However, eye drops are not yet available. Injectable 
vancomycin is routinely used for intravitreal injection (1mg/0.1ml) for the treatment of 
bacterial endophthalmitis. Emergence of vancomycin resistance has been reported in CoNS 
(Schwalbe et al., 1987). Topical ocular formulations of erythromycin are effective for 
conjunctivitis and blepharitis, however clarithromycin and azithromycin are derivatives that 
offer significant advantage over erythromycin owing to their expanded spectra (Barry et al., 
1988). 
Systemic infection with methicillin resistant S. aureus (MRSA) is known to cause morbidity 
and mortality. The prevalence of MRSA in ocular infections varies in different studies. While 
it is reported to be as low as 3% in England (Shanmuganathan et al., 2005), it is high (25-
64%) in Japan (Fukuda et al., 2002). However, Indian workers have also reported increasing 
prevalence of MRSA over the years (Bagga et al., 2010). These authors showed decreased 
susceptibility to fluoroquinolones among MRSA from ocular infections. Shanmuganathan et 
al. (2005) found the MRSA susceptible to chloramphenicol and gentamicin and resistant to 
third generation fluoroquinolones (ciprofloxacin and ofloxacin) and cefazolin.  Topical 
administration of fortified cefazolin (5%) was recommended for the treatment of 
staphylococcal keratitis based on in vitro susceptibility of S. aureus and CoNS (Sharma et al., 
1999, Sharma et al., 2004).  In an ongoing study, 4 of the 45 isolates (8.9%) of S. aureus from 
eye infections were MRSA (Kar et al., 2010). Using microbroth dilution and E test, a high 
level of resistance to fluoroquinolones but susceptibility to cefazolin, vancomycin and 
chloramphenicol was found among both MRSA and MSSA strains (Kar et al., 2010).  
3. Antibiotic resistance 
Antibiotics that are used against Staphylococcus spp. basically target cell wall synthesis, 
protein synthesis, nucleic acid synthesis and other metabolic pathways. The selection 
pressure applied by the antibiotics that are used in clinical and agricultural settings has 
promoted the evolution and spread of genes that confer resistance (Allen et al., 2010). 
Resistance to various antibiotics can be either internal or acquired by horizontal gene 
transfer via various mobile genetic elements like plasmids, transposons, integrons, etc. 
Internal mechanisms include mutational modification of gene targets, over expression of 
various efflux pumps; whereas acquired resistance involves enzymatic inactivation of the 
drug and bypassing of the target. 
Exposure to antibiotics may lead to the formation of persister cells, small colony variants 
(SCVs), biofilms and over-expression of efflux pumps (Lewis, 2008, Singh et al., 2009, Proctor 
et al., 1998, Kwon et al., 2008, Martinez et al., 2009b) (Fig. 1).  Persisters are dormant, multidrug 
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tolerant variants of regular cells that are formed through a combination of stochastic and 
deterministic events in microbial populations (Lewis, 2010). Persisters over express genes such 
as chromosomal toxin-antitoxin modules that shut down their cellular functions, therefore, 
antibiotictarget inducing dormant cell to become tolerant to the lethal action of antibiotics 
(Keren et al., 2004, Singh et al., 2009). Another major problem posed by persister cells is they 
hide at various niches evading the host immune system, such as central nervous system 
(Treponema pallidum), macrophages or granulomas (Mycobacterium tuberculosis), stomach 
(Helicobacter pylori), gallbladder (Salmonella typhi) etc. (Jayaraman, 2008). 
 
Fig. 1. Sub-inhibitory concentrations of antibiotics lead to formation of persister cells (Lewis, 
2010), small colony variants (Proctor et al., 1998), biofilms (Kwon et al., 2008) and over-
expression of efflux pumps (Martinez et al., 2009b). Biofilms are known to harbor cells with 
these kinds of modifications (Singh et al., 2010, Allegrucci and Sauer, 2007, Kvist et al., 2008). 
SCVs have enhanced biofilm forming capability (Singh et al., 2010). Each of these 
mechanisms may lead to multidrug resistance or it may be the combinatorial effect of all the 
above-mentioned processes.  
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SCVs constitute a slow-growing subpopulation of bacteria with distinctive phenotype and 
pathogenic traits (Proctor, 2006). They differ from the normal phenotype in their colony size, 
growth rate, pigmentation, haemolysis, expression of virulence factors, haemin and 
menadione auxotrophy, aminoglycosides and cell wall inhibitors action (Singh et al., 2009). 
Defective respiratory activity serves as the biochemical basis for the development of SCVs 
(Proctor et al., 1998). SCV of S. epidermidis may play a role in the pathogenesis of prosthetic 
valve endocarditis (Baddour and Christensen, 1987), and catheter-induced endocarditis 
(Baddour et al., 1988). Several findings mandate the investigation of small colony variants 
for persistent infections (Proctor et al., 1994, Proctor et al., 1998, Spearman et al., 1996, Kahl 
et al., 1998, Abele-Horn et al., 2000).  
Bacteria in biofilms can tolerate ten to thousand fold higher levels of antibiotics than the 
genetically equivalent planktonic bacteria (Resch et al., 2005).  Staphylococcal biofilms cause 
biomaterial-associated infections which do not respond to antimicrobial treatment often 
requiring removal of the same leading to substantial morbidity and mortality (Gotz and 
Peters, 2000). It has also been observed that biofilms harbour persister cells and small colony 
variants (Singh et al., 2010, Allegrucci and Sauer, 2007) (Fig. 1).  Whereas planktonic persisters 
are eliminated by the immune system in vivo, persisters in biofilms serve as a shield evading 
the immune response (Lewis, 2010). According to Levin and Rozen (Levin and Rozen, 2006), 
a reservoir of such shielded persisters is a potential source for the emergence of heritable 
antibiotic resistance. 
Kvist et al., (2008) reported the enhanced activity of efflux pumps in the bacteria residing in 
the biofilms (Fig. 1). The authors argued that the cramped environment in the biofilm 
demands better waste management leading to escalation of efflux pumps thereby increasing 
the antibiotic resistance of the biofilm cells. Reduction in biofilm formation was observed 
with the addition of efflux pump inhibitors (Kvist et al., 2008). Under physiological 
conditions, efflux pumps are involved in housekeeping activities like detoxification of 
intracellular metabolites, cell homeostasis, intracellular signal trafficking and bacterial 
virulence in animal and plant hosts. However, in the presence of high concentration of 
antibiotics and other environmental factors, they can shift their functional roles (Martinez et 
al., 2009a). 
Antibiotics and their resistance genes were evolved in non-clinical environments in the pre-
antibiotic usage era. Some antibiotics which may serve signalling purposes at the low 
concentration are probably found in natural ecosystems. Resistance determinants to these 
antibiotics were originally selected in their hosts for metabolic purposes or signal trafficking. 
Other antibiotic-resistance genes have been obtained by virulent bacteria through horizontal 
gene transfer (Martinez et al., 2009a). For example, S. aureus mecA gene is located on a 
mobile genetic element, the staphylococcal cassette chromosome mec (SCCmec) (Tsubakshita 
et al., 2010), horizontally acquired from other staphylococcal species S. sciuri (Couto et al., 
1996) and S. fleurettii (Katayama et al., 2000). Also high level of vancomycin resistance is 
associated with carriage of vanA cluster encoded by Tn1546 transposon, first reported in 
Enterococcus species (Uttley et al., 1988). VRSA isolates from Michigan and Pennsylvania 
were found to harbor plasmids of 57.9Kb and 120Kb respectively carrying the transposon 
(Weigel et al., 2003, Tenover et al., 2004). 
Resistance to fluoroquinolones offer a classic example of point mutations (e.g., gyrA&B, 
grlA&B) and efflux mediated resistance (Morar and Wright, 2010). Point mutations in 
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particular regions of each enzyme subunit, known as Quinolone-Resistance-Determining-
Region (QRDR) makes the enzyme less susceptible to inhibition by fluoroquinolones. The 
level of resistance increases in a stepwise manner each time with an additional mutation in 
target enzyme (Hooper, 2001). Selection pressure exerted by enhanced use of quinolones 
have led to the emergence of resistant strains carrying mutations within the endogenous 
transport system that improve affinity of the efflux system for quinolones (Ohshita et al., 
1990, Chopra, 1992). The quinolone resistance in S. aureus  also involves enhanced efflux by 
the Nor family of multidrug efflux pumps (McCallum et al., 2010). Several reports have 
linked increased expression of NorA to reduced susceptibility to chloramphenicol, beta-
lactams, tetracycline, puromycin and some dyes, such as ethidium bromide (McCallum et 
al., 2010, Hooper, 2001, Ruiz, 2003). Point mutations in norA gene have been associated with 
reduced uptake of norfloxacin by the cell (Ohshita et al., 1990). NorB and NorC are the other 
members of Nor family encoding fluroquinolone resistance (Truong-Bolduc et al., 2006).  
Although fluoroquinolones are considered first-line treatment of ocular infections, 85% of 
MRSA are resistant to ophthalmic fluoroquinolones (McDonald and Blondeau, 2010). This 
rise in resistance mandates the need for new agents. Basifloxacin, a novel fluoroquinolone 
was approved as a topical agent for treatment of bacterial conjunctivitis in May 2009 
demonstrated rapid bactericidal activity against isolates that showed in vitro resistance to 
other fluoroquinolones, beta-lactams, macrolides and aminoglycosides (Haas et al., 2010). 
Moreover, basifloxacin lack systemic counterpart, thereby eliminating the contribution of 
systemic use of this drug to the emergence of resistance, although cross resistance from 
other systemic fluoroquinolones is possible (McDonald and Blondeau, 2010). 
The direct relationship between the development of Linezolid (the last-line agent) resistance 
and prolonged exposure of the drug among cystic fibrosis patients was reported by 
Endimiani et al., (2011). Linezolid resistance in S. aureus is uncommon though there are 
reports of mutations in 23S rRNA and ribosomal protein L3 and L4 encoded by rplD gene 
and rplC genes (Locke et al., 2009). However, the most worrisome mechanism involving 
acquisition of the methytransferase cfr that methylates the 23S rRNA associated with mobile 
genetic elements had first been identified in 16.5 kb multi-drug resistance plasmid in 
Staphylococcus sciuri (Kehrenberg et al., 2005).  
4. Therapeutics & therapy 
With the ample evidence of strong association between antibiotic resistance and antibiotic 
consumption the scientific community should also come up with alternative means of 
antibacterial therapies, besides legitimately using available antibiotics, which can be used 
either alone or in conjunction with the antibiotics. Here we discuss some of the alternative 
strategies including vaccine development, phage therapy, use of lytic enzymes and plant-
derived antibacterials. There are some reports on the use of nanoparticles as an efficient 
means of delivering antibacterials. 
4.1 Staphylococcal vaccines 
S. aureus has devised various mechanisms to evade the immune system. (i) two 
immunoglobulin binding proteins (protein A and Sbi), (ii) immune cell lysing toxins (Hlg, 
PVL), (iii) proteins interfering with complement activation (SCIN– staphylococcal 
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complement inhibitor) and (iv) chemotaxis of neutrophils inhibiting peptides.  Production of 
superantigens by S. aureus leads to allergy and immunosuppression. S. epidermidis relies 
primarily on cell-surface polymers and the ability to form a biofilm to survive in the host 
(Foster, 2005). However, protective role of antistaphylococcal antibodies from 
staphylococcal infection has been well documented in literature (Dryla et al., 2005). 
Holtfreter and Broker (2005) reported that carriers have high titers of neutralizing antibodies 
specific for those superantigens that are expressed by their colonizing strain. This carriage 
status confers strain specific humoral immunity, which may contribute to protection during 
S. aureus septicemia. Substantial controversy exists as to whether staphylococcal infections 
may be prevented by vaccination and, if so, which antigens should be selected and patients 
targeted for vaccination. In a comprehensive review on immune-therapeutics for 
staphylococcal infections by Ohlsen and Lorenz (2010) described the necessity for the 
development of both passive and active immunotherapies against Staphylococcus. The 
underlying criteria for the selection of targets e.g. gene products or toxins, should be 
conservability and expression in most of the clinical isolates. 
4.1.1 MSCRAMM (Microbial Surface Component Recognizing Adhesive Matrix 
Molecules)  
Some of the surface proteins of S. aureus have been exploited for immunotherapy. MSCRAMM 
protein family represents prototype of targets because of their exposed location and virulence 
involvement (Ohlsen and Lorenz, 2010, Flock, 1999). The best characterized MSCRAMM 
proteins include (i) clumping factor B (clfB), (ii) collagen-binding protein (Cna), and (ii) 
fibronectin-binding protein (FnBPA) (Ohlsen and Lorenz, 2010, Garcia-Lara et al., 2005). 
Veronate (Inhibitex) was developed by including anti-clfA and SdrG (S. epidermidis protein) 
from selected human donors (Patti, 2005), but failed to reach its target endpoints for the 
protection because of low birth weight babies at clinical trial III (Ohlsen and Lorenz, 2010).  
Aurexis® is a humanized monoclonal antibody that recognizes clumping factor A (ClfA), a cell 
surface protein expressed by virtually all strains of S. aureus. Aurexis® binds with high affinity 
and specificity and interferes with S. aureus ability to colonize and spread to fibrinogen 
containing substrates such as wound sites, biomaterial coated implants, and damaged 
endovascular tissues. Inhibitex is actively seeking a corporate partner(s) for the continued 
clinical development of Aurexis® (http://www.inhibitex.com/Pipeline/Partnerships.html). 
Antibodies against clumping factor B (clfB) (Schaffer et al., 2006), Cna (Mamo et al., 2000), 
FnBPA (Zhou et al., 2006) have shown promising results. However, antibodies against 
against these targets have not yet been included in clinical trials (Ohlsen and Lorenz, 2010). 
Stranger-Jones et al., (2006) reported that the combination of four surface proteins IsdA, 
IsdB, SdrB, and SdrE afforded high level of protection against invasive disease or lethal 
challenge with human clinical S. aureus isolates. 
4.1.2 Capsule 
Capsular polysaccharides (CPs) represent the best established targets for vaccine-induced 
immunity to bacterial cells. About 70%–80% of S. aureus strains produce one of two CP 
antigens e.g. CP5 or CP8 (Skurnik et al., 2010). Nabi pharmaceuticals developed a vaccine 
StaphVaxTM conjugating CP5 and CP8 to detoxified Pseudomonas aeruginosa exoprotein A, that 
failed to protect haemodialysis patients against S. aureus infections (Ohlsen and Lorenz, 2010, 
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Shinefield et al., 2002). To enhance the efficacy of StaphVaxTM, PentastaphTM -pentavalent S. 
aureus vaccine was developed that included surface polysaccharide component 336, PVL and 
alpha-toxin to eliminate S. aureus by phagocytosis and neutralizing bacterial toxins. This 
vaccine has been evaluated in Phase II for safety and immunogenicity (Ohlsen and Lorenz, 
2010).  
4.1.3 Biofilm as the vaccine target 
Although the significance of biofilm in infections has been recognized, there has not been 
much effort to develop vaccine targeting biofilms. The possible target sites for vaccine 
development may be the bacterial cells within the biofilm and/or biofilm matrix (Harro et 
al., 2010). Cerca et al., (2007) reported that an antibody developed against Staphylococcus 
Poly-N-acetyl glucosamine (PNAG) was found effective against different strains of E. coli. In 
another report, effectiveness of PNAG as vaccine candidate in S. aureus mediated skin 
abcesses and lethal E. coli peritonitis was demonstrated (Gening et al., 2010). However, 
PNAG may not be an ideal vaccine candidate against those strains possessing icaADBC 
locus because it is not produced in all biofilm-producing staphylococcal strains (Harro et al., 
2010, Rohde et al., 2001). Therefore, it was suggested that vaccine studies should be focussed 
on the cell embedded in the matrix rather than the matrix. A proteomic approach of looking 
into the comparative proteomes of the planktonic and biofilm cells may be an interesting 
area to start with (Harro et al., 2010). 
4.1.4 Whole cell vaccine 
Vaccine Research International (http://www.vri.org.uk/) is developing a vaccine (SA75) 
using chloroform killed whole cells of S. aureus. Phase I clinical trials have been successfully 
completed. The whole cell preparation could provide a broad spectrum of S. aureus antigens 
in a single vaccine some of which had immune-stimulatory affect and act as an adjuvant 
generating higher antibody response against protective antigens. However, the mechanism 
of action is unknown and down-regulation of immune pathways by components of the 
vaccine cannot be ruled out (Ohlsen and Lorenz, 2010). 
4.1.5 Staphylococcal enterotoxin as a vaccine candidate 
Virulence factor-specific antibodies derived from vaccination or employed as therapeutics 
represent a potential defense against bacterial diseases (Larkin et al., 2010). Staphylococcal 
enterotoxins are considered potential biowarfare agents that can be spread through 
ingestion or inhalation (Drozdowski et al., 2010). Staphylococcal enterotoxins (SEs) and 
related toxic shock syndrome toxin-1 (TSST-1) act as superantigens. These protein toxins can 
cause acute gastroenteritis and toxic shock syndrome. There are more than twenty different 
SEs described to date with varying amino acid sequences, common conformations, and 
similar biological effects. Picomolar concentrations of these superantigenic toxins activate 
specific T-cell subsets after binding to major histocompatibility complex class II. Activated 
T-cells vigorously proliferate and release proinflammatory cytokines plus chemokines that 
can elicit fever, hypotension, and other ailments which include a potentially lethal shock 
(Larkin et al., 2009, Varshney et al., 2010).  
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Studies on the protective effect of non-toxic mutant GST–mTSST-1 fusion protein against 
staphylococcal infection, was purified and tested. Mice were immunized with the GST–
mTSST-1 plus alum adjuvant and challenged with viable S. aureus. The results indicate the 
efficacy of this protein in the elimination of bacterial load from the organs as well as in the 
inhibition of production of pro-inflammatory cytokines due to TSST-1 in the splenic cells. 
Furthermore immunization with GST–mTSST-1 strongly induced the production of TSST-1 
specific antibodies, especially immunoglobulin G1 and immunoglobulin G2b (Cui et al., 
2005). 
Varshney et al., 2010 showed that four murine monoclonal antibodies bind to conformational 
epitopes that are destroyed by deletion of the distal C-terminal 11 Amino acids (Varshney et 
al., 2010). This study, for the first time, showed that MRSA derived SEB (staphylococcal 
enterotoxin B) contains a deletion in the C-terminal, which affects binding of certain protective 
Abs. This study also demonstrated enhanced protection against SEBILS (SEB induced Lethal 
Shock) when two non-protective mAbs were combinedly administered in vivo.  
Drozdowski et al., (2010) generated high-affinity SEB-specific antibodies capable of 
neutralizing SEB in vitro as well as in vivo in a mouse model. They described for the first 
time recombinantly-derived human monoclonal antibodies against SEB that possess high 
affinity, target specificity, and therapeutic potential for superantigen-induced toxic shock. 
These antibodies prevent intoxication by interfering with toxin binding to MHC II and/or 
TCR. In addition to potential applications for treating toxic shock syndrome, human 
monoclonal antibodies recognizing SEB or other bacterial superantigens may be useful if 
employed as an adjunct therapy with antibiotics in treating S. aureus infections. 
STEBvax is a new vaccine developed against toxic shock syndrome. It is currently under 
clinical trial phase I. The vaccine is being tested for prophylactic and therapeutic use 
(http://clinicaltrials.gov/ct2/show/NCT00974935) . 
Larkin et al., (2010) selected human monoclonal antibodies from a phage display library, 
using a recombinant SEB vaccine (STEBVax) incorporating site-specific mutations that 
prevent MHC II interactions. This group discovered that some antibody clones cross-react 
with SEC1, SEC2, and streptococcal pyrogenic exotoxin C (SpeC), while others were highly 
specific for SEB. Many of the antibodies effectively inhibited T-cell activation by SEB in 
vitro, bound to toxin with nanomolar affinity, and prevented SEB-induced toxic shock in 
vivo. This recombinantly-derived, human monoclonal antibodies against SEB had high 
affinity, target specificity, and therapeutic potential for superantigen-induced toxic shock. 
These antibodies prevented intoxication by interfering with toxin binding to MHC II and/or 
T-cell antigen receptors. The author suggested the potential applications for treating toxic 
shock syndrome, human monoclonal antibodies recognizing SEB or other bacterial 
superantigens may be useful if employed as an adjunct therapy along with antibiotics in 
treating difficult S. aureus infections (Larkin et al., 2010). 
4.1.6 Future perspectives in vaccine development 
As discussed earlier, comparative proteomic analysis of planktonic and biofilm cells is an 
interesting area to look for vaccines against biofilm. Another important strategy is to look 
for immunodominant antigens. This strategy has led to the identification of a wide range of 
surface and extracellular target antigens such as IsdB, GrfA, IsaA, IsaB, Atl, IsdA, IsdH, 
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FmtB, SspA, SspB and Lip (Lorenz et al., 2000, Etz et al., 2002, Clarke and Foster, 2006). The 
rationale behind such a strategy is that the patients may develop antibodies against specific 
staphylococcal antigens during infection that may be critical for combating the infections 
(Ohlsen and Lorenz, 2010). 
Another promising strategy is the reduction of nasal colonization by S. aureus as several 
studies have shown that nasal carriers have increased risk of developing infections by 
endogenous strains (von Eiff et al., 2001, Wertheim et al., 2004). Vaccination with clumping 
factor B, iron-responsive surface determinants (Isd) A and H, teichoic acid and capsular 
polysaccharides have been reported to reduce the nasal colonization with S. aureus (Dryla et 
al., 2005, Clarke and Foster, 2006). 
4.2 Phage therapy 
The rise of multidrug resistant bacteria has enforced the resurgence of phage therapy in the 
West, though this mode of therapy is being practiced for several years in Eastern Europe. 
Some of the success stories on phage therapy are described here. The Eliava Institute in 
Tbilisi, Republic of Georgia, has developed a highly virulent, monoclonal staphylococcal 
bacteriophage active against 80-95% of S. aureus strains including MRSA. This product was 
used for local and generalized infections, including neonatal sepsis, osteomyelitis, wound 
infections, pneumonia etc. (Hanlon, 2007). There are some polyvalent obligate lytic S. aureus 
phages e.g. phage phi812, phageK and phage44AHJD which have been successfully tested 
for their efficacy in killing S. aureus including MRSA strains (Mann, 2008).  Evaluation of 
phageK showed marked reduction of pathogenic and antibiotic resistant coagulase positive 
and negative staphylococci associated with bovine and human infections that included S. 
aureus, S. epidermidis, S. saprophyticus, S. chromogenes, S. capitis, S. hominis, S. haemolyticus, S. 
caprae, and S. hyicus. The modified phage generated by passing through less susceptible 
target strain can be used in combination with phageK to increase the host range. This study 
had also shown the potential of delivering the phage in the form of handwash or 
antistaphylococcal cream (O'Flaherty et al., 2005b). Merabishvili and colleagues (2009), 
demonstrated laboratory-based production and quality control of a cocktail, currently under 
evaluation, consisting of exclusively lytic bacteriophages for the treatment of Pseudomonas 
aeruginosa and S. aureus infections of burn wound.  
Curtin and Donlan (2006), reported use of phage e.g. phage456, in reducing the biofilm 
formation and adherence of S. epidermidis biofilms on both hydrogel-coated and 
serum/hydrogel coated silicone catheters. The presence of divalent cations in the growth 
medium (Mg++, Ca++) further increased the efficacy of phage456 in reducing biofilm 
formation. Polyvalent Staphylococcus phage combined with highly efficient Pseudomonas T7-
like phage (phage phiIBB-PF7A) effectively showed reduction in dual species biofilms, 
killing and finally removal of bacteria from the host substratum (Sillankorva et al., 2010).  
There were efforts to engineer bacteriophage by over-expressing proteins to target gene 
networks, particularly non-essential genes, to enhance bacterial killing by antibiotics. Using 
this approach, Lu and Collins (2007), engineered a T7 phage which significantly reduced 
Escherichia coli biofilm. They claim that this combinatorial approach may reduce the 
incidence of antibiotic resistance and enhance bacterial killing. 
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There are many advantages of using phage in therapeutics. (i) Dysbiosis can be avoided due 
to their specificity, (ii) Multiple administrations are not required because phage replicates at 
the site of infection, (iii) Phage could select resistant mutants of the selected bacteria, and 
(iv) Selection of new phages is rapid compared to the development of new antibiotic which 
may take several years. However, the disadvantage is that the causal organism needs to be 
identified before administering the phage (Sulakvelidze et al., 2001). Moreover, prior to the 
extensive therapeutic use of phages it is prudent to ensure the safety of therapeutic phages. 
The phages should not carry out generalized transduction and possess gene sequences 
having significant homology with known antibiotic resistances, phage-encoded toxins and 
other bacterial virulence factors (Sulakvelidze et al., 2001).  
4.3 Antistaphylococcal lytic enzymes 
Antistaphylococcal lytic enzymes can be broadly divided into two groups: (i) Staphylococcal 
phage lysins (endolysins) and (ii) Bacteriocins (e.g. Lysostaphin) (Borysowski and Gorski, 
2009a). 
4.3.1 Lysins  
Lysins are enzymes, consist of N-terminal catalytic domain and C-terminal bacterial cell-
wall binding domain, and are produced by bacteriophage that digests the bacterial cell wall 
(Fischetti, 2010, Borysowski and Gorski, 2009a). LysK, highly specific for the genus 
Staphylococcus, was obtained from phageK, has been effectively used in the treatment of 
staphylococcal infections (O'Flaherty et al., 2005a). Interestingly MV-L derived from 
bacteriophage phiMRII was found specific to S. aureus and S. simulans infection (Rashel et 
al., 2007). This phage also acted synergistically with glycopeptide antibiotics against VISA 
and MRSA. Moreover, MV-L induced antibodies could not abolish the bacteriolytic activity. 
Endolysin from another phi11 showed elimination of S. aureus NCTC8325 biofilm but not of 
S. epidermidis O-47 biofilm (Sass and Bierbaum, 2007). Purified endolysin (MW 53.3kDa) 
from virulent S. aureus bacteriophage Twort, plyTW, demonstrated cleavage of 
staphylococcal peptidoglycan. Upstream of plyTW there is Twort holin gene, holTW, which 
produces unspecific holes in the bacterial cytoplasmic membrane, degrade staphylococcal 
peptidoglycan through hydrolysis of alanine amino bonds (Loessner et al., 1998). CHAP 
(cysteine-histidine dependent amidohydrolase/ peptidase) exhibits lytic activity against 
staphylococcal isolates including MRSA, was identified by deletion analysis of LysK 
domain. CHAP can be used as single domain for therapeutic purposes over the whole 
enzyme as this may lower the risk of immunogenic response (Horgan et al., 2009). 
4.3.2 Synergistic effect of lysins 
Manoharadas et al., (2009) constructed a chimeric endolysin (P16-17) consisting of N-
terminal D-alanyl-glycyl endopeptidase domain and C-terminal P16 endolysin domain and 
P17 minor coat protein, targeting cell wall of S. aureus phage. This domain swapping 
approach and subsequent purification resulted in finding soluble P16-17 protein, which 
exhibited antimicrobial activity against S. aureus. This protein further augmented the 
antimicrobial efficacy of gentamicin suggesting synergistic effect in reducing effective dose 
of aminoglycosides. Synergistic effect of nisin and LysH5, the endolysin encoded by phi-
SauS-IPLA88 was demonstrated (Garcia et al., 2010). It was suggested that better lytic 
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enzymes can be constructed by using methods like protein engineering, domain swapping 
and gene shuffling. Owing to the non-existence of bacterial resistance to lysins someday 
phage lytic enzymes could be an essential strategy to combat pathogenic bacteria (Fischetti 
et al., 2010).  
4.3.3 Lysostaphin as a therapeutic agent 
Lysostaphin, a 25kDa protein possessing two functional domains: N-terminal catalytic 
domain and C-terminal cell wall binding domain B, is a plasmid-encoded extracellular 
enzyme produced by S. simulans biovar staphylolyticus (Borysowski and Gorski, 2009b). It is 
a Zn-containing endopeptidase that specifically cleaves the bonds between the glycine 
residues in the interpeptide cross-bridges of the staphylococcal peptidoglycan resulting in 
the hypotonic lysis of the bacterial cell (Kumar, 2008). There are several reports of 
lysostaphin mediated lysis of clinically relevant antibiotic resistant staphylococcal strains. 
Lysostaphin which is readily absorbed onto catheter surfaces without losing lytic property 
shows promise in the prevention of catheter-related bloodstream infections caused by CoNS 
and S. aureus (Shah et al., 2004, Borysowski and Gorski, 2009a). Lysostaphin has successfully 
eradicated nasal colonization of MSSA, MRSA and mupirocin-resistant S. aureus in 
experimental cotton rats (Kokai-Kun et al., 2003). In combination with lysostaphin, oxacillin 
or vancomycin, showed increased efficacy against MRSA (Kokai-Kun et al., 2007, Patron et 
al., 1999). Several workers demonstrated the effectiveness of lysostaphin in the treatment of 
biofilms formed by S. aureus and S. epidermidis and disruption of biofilms on glass and 
plastic surfaces (King et al., 1980, Walencka et al., 2005, Wu et al., 2003). Evaluation of 
PEGylation potential in improving lysostaphin pharmacokinetics showed substantial 
increase in serum drug half-life and reduced binding to anti-lysostaphin antibodies while 
maintaining the enzyme's lytic activity (Walsh et al., 2003). 
4.3.4 Lysostaphin therapy in ocular infections 
Lysostaphin was also tested as a potential means of treating some ocular infections, especially 
endophthalmitis and keratitis.  Dajcs et al., (2001) demonstrated the effect of lysostaphin on 
MRSA endophthalmitis in the rabbit model. Lysostaphin when administered twice after 8h 
and 24h post-infection showed 88% and 50% sterilization compared to 0% sterilization in 
untreated controls. However, the severity of ocular inflammation could be controlled only on 
8h post-infection treatment models. Lysostaphin as a probable immunizing agent was also 
investigated. In this study, rabbits were immunized with lysostaphin by subcutaneous, 
intranasal or intraocular route that showed successful retention of bactericidal activity in vivo, 
in spite of the high titre of anti-lysostaphin antibodies (Dajcs et al., 2002, Balzli et al., 2010). 
4.3.5 Synergistic effects 
Synergistic inhibition by ranalexin (a cationic peptide) in combination with lysostaphin 
resulted in an enhanced bactericidal effect. This finding, therefore, suggested that dressings 
could be impregnated with ranalexin and lysostaphin to treat wound infections caused by 
MRSA (Graham and Coote, 2007, Desbois et al., 2010). Furthermore lysozyme has been 
reported enhancing lysostaphin activity (Cisani et al., 1982). Combinatorial action of various 
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beta-lactam antibiotics or mupirocin or gentamicin enhancing lysostaphin activity was 
reported by various groups (Polak et al., 1993, Climo et al., 2001, Kiri et al., 2002, LaPlante, 
2007). Thus, it is concluded that lysostaphin is an effective agent as pre- and post-treatment 
option for staphylococcal infections though CoNS showed generally weaker effect than S. 
aureus (Borysowski and Gorski, 2009a). This was because of presence of higher amount of 
serine than glycine in peptidoglycan of coagulase-negative staphylococci (Kumar, 2008). 
4.4 Plant-derived antibacterials 
Plant-derived antibacterials are of three types: (i) traditional antibiotics, (ii) antibacterials 
that target bacterial virulence, and (iii) inhibitors of MDR pump. The first two categories 
have not been explored in detail (Lewis and Ausubel, 2006). The details of third category of 
compounds obtained from plant sources, their properties as MDR/ EPI inhibitors and its 
use as antibacterial against staphylococcal infection are summarized in Table 2.  
Identification of EPIs from natural sources is still in infancy. However, the chemical 
diversity of plants and microorganisms and their requirement for nutrients to synthesize 
such compounds should make the search for EPIs from such sources an attractive option 
(Stavri et al., 2007). 
4.5 Nature's backyard 
Resistance of microbial pathogens to antibiotics is a serious threat to the well-being of 
mankind. Recently, two small molecules, platensimycin, identified from strain of 
Streptomyces platensis isolated from soil sample in South Africa, by using antisense 
differential sensitivity whole-cell screening program, targeting the fatty acid biosynthesis 
pathway of gram-positive bacteria. The platensimycin (C24H27NO7, MW 441.47) comprises of 
two distinct structural element connected by an amide bond, is active against MRSA, VISA, 
Vancomycin-resistant enterococci and linezolid and macrolide resistant pathogens (Wang et 
al., 2006) (Fig. 2A). 
Continued screening led to the discovery of platencin (C24H27NO6, MW 425.2), a novel 
product that is chemically and biologically related to platensimycin which exhibits broad-
spectrum antibacterial activity against gram positive bacteria which inhibit fatty acid 
biosynthesis (Fig. 2B). These molecule targets two essential proteins, beta-ketoacyl synthase 
II (FabF) and III (FabH) (Wang et al., 2007). These studies reflect upon the fact that nature 
holds the treasure trove of antibiotics which are yet to be explored. 
 
Fig. 2. Chemical structure of Platensimycin (A) and Platencin (B). 
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 Common 
name & 
plant species 
name  
Compound Properties  Total 
effect 
Synergistic 
effect  
References 
1 Barberry & 
Berberis 
species 
Berberine & 5’-
methoxyhydnocarpin
Hydrophobic cation 
increases membrane 
permeability and 
intercalate DNA 
Inhibit 
MDR 
Antibacterial (Stermitz et 
al., 2000) 
2 Golden seal 
& Hydrastis 
canadensis 
Berberine & 5’-
methoxyhydnocarpin
5’-
methoxyhydnocarpin- 
linking of berberine to 
INF55 
Inhibit 
MDR 
Antibacterial (Ball et al., 
2006) 
3 Silvery 
lupine & 
Lupinus 
argenteus 
Isoflavones Enhances activity of 
berberine and 
norfloxacin 
Inhibit 
MDR 
Antibacterial (Morel et 
al., 2003) 
4 Fabaceae & 
Dalea 
versicolor 
Phenolic metabolites Enhances activity of 
berberine, 
erythromycin and 
tetracycline 
Inhibit 
MDR 
Antibacterial (Belofsky et 
al., 2004)] 
5 Smoke tree 
& Dalea 
spinosa 
2-arylbenzofuran 
aldehyde & Phenolic 
compounds; 
SpinosanA, 
Pterocarpan & 
Isoflavone 
Enhances activity of 
berberine 
Inhibit 
MDR 
Antibacterial  (Belofsky et 
al., 2006) 
6 Tea Epicatechin gallate & 
Epigallocatechin 
gallate 
Enhances activity of 
norfloxacin and 
tetracycline 
Inhibit 
MDR  
Antibacterial  (Gibbons et 
al., 2004, 
Sudano 
Roccaro et 
al., 2004) 
7 Rosemery & 
Rosmarinus 
officinalis 
Diterpines, Carnosic 
acid & Carnesol 
Potentiate activity of 
tetracycline  and 
erythromycin 
Inhibit 
MDR 
Antibacterial (Oluwatuyi 
et al., 2004) 
8 Gipsywort 
& Lycopus 
europaeus 
Lipophilic extract Potentiate activity of 
tetracycline and 
erythromycin 
Inhibit 
MDR 
Antibacterial (Gibbons et 
al., 2003) 
9 Grapefruit 
oil & Citrus 
paradisi 
Coumarin derivative: 
Bergamottin epoxide 
& Coumarin epoxide 
Enhances activity of 
ethidium bromide 
and norfloxacin  
Inhibit 
MDR 
Antibacterial (Abulrob et 
al., 2004) 
10 Piperine & 
Piper nigrum 
& Piper 
longum 
Piperine Potentiating action of 
piperine in 
combination with 
ciprofloxacin  
Inhibit 
MDR 
Antibacterial (Khan et al., 
2006) 
Table 2. Properties of MDR/ EPI inhibitors isolated from medicinal plants and its use as 
antibacterial agent against Staphylococcal infection. 
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5. Conclusions 
Extensive applied and basic research is needed to come up with strategies combating the 
major challenges of staphylococcal infections. Recently, folic acid tagged chitosan 
nanoparticles were effectively used to deliver vancomycin. It proved to be an efficient method 
to increase the bioavailability of the same (Chakraborty et al., 2010). Researchers have 
developed Nitric oxide releasing nanoparticles as treatment for skin and soft tissue infections 
successfully tested in murine models (Han et al., 2009, Englander and Friedman, 2010). 
Use of vaccines and phages for the treatment and control staphylococcal infections might be 
a sustainable alternative to antibiotics. The advent of high throughput sequencing has led to 
the analysis of phage genomes and better understanding of phage evolution, phage-host 
interaction, bacterial pathogenicity, phage ecology and origin of phages (O'Flaherty et al., 
2009). With the background knowledge of phage genomics, it will be possible to approach 
phage therapeutics cautiously and effectively. Future research should focus on 
multidisciplinary approach on the development of alternative/conjunctive strategies for 
treatment and prevention of staphylococcal infections. 
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